Rand Eye Institute Director of Vitreo-Retinal Services Dr. Carl Danzig is the first in South Florida to administer an investigational gene therapy for people with dry age-related macular degeneration, commonly known as AMD.
The clinical trial, called Horizon, involves a single, one-time injection under the retina at the back of the eye to deliver this gene therapy.
“This is different than wet macular degeneration, which people know about, that takes place in the office. This is in the operating room, where we enter the eyeball and we go under the retina with a very tiny needle and we inject some gene therapy, and what this does, it provides instructions for your own cells to produce a natural regulatory protein that you already have and basically upregulate that — you make that more and therefore, hopefully, fight the progression of this disease,” Danzig said.
Click the link below to watch the full interview as seen on Local 10 HealthCAST with Kristi Krueger.